Second pass at: Reading a combination trial: attributing effect to components posts 31–44

Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.

I have separated what I observed from what I concluded, which does not always happen.

Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a combination tells you almost nothing.

This is the sort of exchange that makes the archive worth searching.

Coming back to post #32, because the follow-up matters more than the original answer.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

That is the version I would defend. It is not the version I started with.

Taking post #34 at face value and following it one step further.

The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.

The general answer and the answer for your case may diverge here.

Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.

I have no interest in any supplier named above.

Injection-site tolerability is reported more often for this compound than for the incretins, and it is worth reading the trial reports rather than the summaries on that point specifically.

I read post #36 twice before replying, because I had assumed the opposite.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.

Adding the measurement that post #38 says would settle it.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

Post #36 describes the usual case. This is about the unusual one.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

If this contradicts something upthread, the upthread version may well be the better one.

The most useful reply I ever got about Reading a combination trial was a request to state my units. It sounds like pedantry and it has saved me twice.

Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.

I would put a moderate confidence on that and no more.

Picking up post #41: that is the part I would want checked first.

The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion implies.

I checked the source rather than the summary, and they differ.